GeneDx Holdings (WGS) Capital Leases (2020 - 2021)

GeneDx Holdings (WGS) posted quarterly Capital Leases of $18.4 million for Q4 2021, down 11.31% year-over-year from $20.8 million in Q4 2020, and down 11.31% quarter-over-quarter from $20.8 million in Q4 2020.

GeneDx Holdings (WGS) Capital Leases (2020 - 2021) Analysis & Trends

GeneDx Holdings (WGS) has reported Capital Leases for 2 consecutive years, with $18.4 million the latest figure, recorded in Q4 2021.

  • In Q4 2021, Capital Leases fell 11.31% year-over-year to $18.4 million; the TTM figure through Dec 2021 stood at $18.4 million (down 11.31% YoY), while the FY2021 annual figure was $18.4 million, down 11.31% from the prior year.
  • Capital Leases eased to $18.4 million in Q4 2021 per WGS's latest filing, from $20.8 million in the prior quarter.
  • Across five years, Capital Leases topped out at $20.8 million in Q4 2020 and bottomed at $18.4 million in Q4 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Thermo Fisher Scientific 213.88 Bn 209.81 Bn 8.34 Bn
2 Danaher 140.65 Bn 136.30 Bn 3.61 Bn
3 Idexx Laboratories 46.02 Bn 45.83 Bn 779.09 Mn
4 Agilent Technologies 39.85 Bn 38.05 Bn 990.00 Mn
5 Iqvia Holdings 39.20 Bn 37.12 Bn 1.44 Bn
6 Natera 38.80 Bn 37.70 Bn 696.04 Mn
7 Illumina 30.11 Bn 28.94 Bn 770.00 Mn
8 Mettler Toledo International 28.66 Bn 28.61 Bn 650.22 Mn
9 Quest Diagnostics 26.24 Bn 25.61 Bn 1.03 Bn
10 GeneDx Holdings 2.08 Bn 1.94 Bn 78.24 Mn

Historic Data

Download Data
DateValue
Dec 31, 2021 18.43 Mn
Dec 31, 2020 20.78 Mn